Department of Neuropathology, Sainte-Anne Hospital, Paris, France.
Paris V Descartes University, Paris Cité Sorbonne, Paris, France.
Brain Pathol. 2019 May;29(3):325-335. doi: 10.1111/bpa.12664. Epub 2018 Nov 28.
Ependymoma with RELA fusion has been defined as a novel entity of the revised World Health Organization 2016 classification of tumors of the central nervous system (CNS), characterized by fusion transcripts of the RELA gene and consequent pathological activation of the NFkB pathway. These tumors represent the majority of supratentorial ependymomas in children. The validation of diagnostic tools to identify this clinically relevant ependymoma entity is essential. Here, we have used interphase fluorescent in situ hybridization (FISH) for C11orf95 and RELA, immunohistochemistry (IHC) for p65-RelA and the recently developed DNA methylation-based classification besides conventional histopathology, and compared the precision of the methods in 40 supratentorial pediatric brain tumors diagnosed as ependymomas in the past years. Reverse transcription PCR (RT-PCR) and RNA sequencing were performed to explore discordant cases. Furthermore, we integrated imaging and clinical features as additional layers of information. The concordance between nuclear RelA expression by IHC and RELA FISH was 100%. Concordance between IHC and DNA methylation profiling, and between FISH and DNA methylation profiling was also high (96.4% and 95.2%, respectively). Thirty-four out of 40 (85%) cases were confirmed by integrated diagnoses as ependymal tumors, including 22 RELA-fused ependymomas (71% of ependymal tumors), two YAP1-fused ependymomas (6%), six non-RELA/non-YAP1 ependymomas (18%) and four ependymal/subependymal mixed tumors (12%). Ependymal/subependymal mixed tumors had an excellent clinical outcome despite the presence of histopathological signs of malignancy, suggesting that these tumors should not be diagnosed as classic ependymomas. DNA methylation profiling helped in the differential diagnosis of RELA-fused ependymomas. IHC and FISH, which are available in the majority of pathology laboratories, are valuable tools to identify RELA-fused ependymomas.
具有 RELA 融合的室管膜瘤已被定义为修订版 2016 年世界卫生组织中枢神经系统(CNS)肿瘤分类中的一个新实体,其特征是 RELA 基因的融合转录本,随后 NFkB 途径发生病理性激活。这些肿瘤代表了儿童幕上室管膜瘤的大多数。验证用于识别这种具有临床相关性的室管膜瘤实体的诊断工具至关重要。在这里,我们使用间期荧光原位杂交(FISH)检测 C11orf95 和 RELA、免疫组织化学(IHC)检测 p65-RelA 以及最近开发的基于 DNA 甲基化的分类方法,除了常规组织病理学,在过去几年中诊断为室管膜瘤的 40 例幕上儿童脑肿瘤中比较了这些方法的精度。进行逆转录 PCR(RT-PCR)和 RNA 测序以探索不一致的病例。此外,我们整合了影像学和临床特征作为额外的信息层。IHC 核 RelA 表达与 RELA FISH 的一致性为 100%。IHC 与 DNA 甲基化谱分析之间以及 FISH 与 DNA 甲基化谱分析之间的一致性也很高(分别为 96.4%和 95.2%)。通过综合诊断,40 例中的 34 例(85%)被确认为室管膜瘤,包括 22 例 RELA 融合的室管膜瘤(71%的室管膜瘤)、2 例 YAP1 融合的室管膜瘤(6%)、6 例非 RELA/非 YAP1 室管膜瘤(18%)和 4 例室管膜/室管膜下混合瘤(12%)。尽管存在恶性组织病理学特征,但室管膜/室管膜下混合瘤具有极好的临床结局,这表明这些肿瘤不应被诊断为经典室管膜瘤。DNA 甲基化谱分析有助于 RELA 融合的室管膜瘤的鉴别诊断。在大多数病理实验室都可获得的 IHC 和 FISH 是识别 RELA 融合的室管膜瘤的有价值的工具。